AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
With a market cap of 406.82B, AbbVie(ABBV) trades at $229.85. The stock has a price-to-earnings ratio of 98.41 and currently yields dividends of 2.9%.
During the trading session on 2026-03-06, AbbVie(ABBV) shares reached a daily high of $232.72 and a low of $226.80. At a current price of $229.85, the stock is +1.3% higher than the low and still -1.2% under the high.
Trading volume for AbbVie(ABBV) stock has reached 6.09M, versus its average volume of 6.48M.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
ABBV News
AbbVie ABBV reported encouraging fourth-quarter and full-year 2025 results last month. While the company’s immunology portfolio accounted for the bulk of revenu...
AbbVie (NYSE:ABBV) plans to invest US$380 million in two new US active pharmaceutical ingredient manufacturing facilities that will use artificial intelligence...
Image source: The Motley Fool. Thursday, March 5, 2026 at 8 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Curran Simpson Chief Medical Offi...
Analyst ratings
64%
of 33 ratingsMore ABBV News
AbbVie ( (ABBV) ) has issued an update. On March 4, 2026, AbbVie completed an underwritten public notes offering totaling $8 billion, spanning a mix of senior...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie is running a Phase 2 study in Japan to test venetoclax in adults with relapsed or ref...
Key Points AbbVie had 10 therapies with sales of $1 billion or more each in 2025. The pharma giant has raised its dividends annually for 54 consecutive years....
AbbVie recently reported positive topline Phase 3 results from its AFFIRM trial, showing risankizumab (SKYRIZI) subcutaneous induction led to significantly high...
New insider activity at AbbVie ( (ABBV) ) has taken place on March 3, 2026. EVP, General Counsel and Secretary Perry C. Siatis has executed a notable stock sal...
AbbVie Inc. (NYSE:ABBV) on Monday revealed topline results from the Phase 3 AFFIRM study evaluating the efficacy of risankizumab in treating Crohn’s disease. Th...
AbbVie’s (ABBV) treatment of neuroendocrine carcinoma was granted FDA orphan designation, according to a post on the agency’s website. Published first on TheFl...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.